Citigroup’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.96M | Sell |
517,247
-13,612
| -3% | -$131K | ﹤0.01% | 1420 |
|
|
2025
Q1 | $3.33M | Buy |
530,859
+486,282
| +1,091% | +$3.05M | ﹤0.01% | 1712 |
|
|
2024
Q4 | $362K | Buy |
44,577
+13,056
| +41% | +$106K | ﹤0.01% | 3225 |
|
|
2024
Q3 | $570K | Buy |
31,521
+22,665
| +256% | +$410K | ﹤0.01% | 2913 |
|
|
2024
Q2 | $91.2K | Buy |
8,856
+2,811
| +47% | +$29K | ﹤0.01% | 3533 |
|
|
2024
Q1 | $64.2K | Buy |
6,045
+396
| +7% | +$4.21K | ﹤0.01% | 3764 |
|
|
2023
Q4 | $51.6K | Buy |
5,649
+1,821
| +48% | +$16.6K | ﹤0.01% | 3753 |
|
|
2023
Q3 | $39.7K | Sell |
3,828
-5,256
| -58% | -$54.5K | ﹤0.01% | 3519 |
|
|
2023
Q2 | $130K | Buy |
9,084
+8,138
| +860% | +$117K | ﹤0.01% | 3442 |
|
|
2023
Q1 | $6.75K | Sell |
946
-186
| -16% | -$1.33K | ﹤0.01% | 4191 |
|
|
2022
Q4 | $12.7K | Sell |
1,132
-115
| -9% | -$1.29K | ﹤0.01% | 4061 |
|
|
2022
Q3 | $14K | Sell |
1,247
-1,262
| -50% | -$14.2K | ﹤0.01% | 4156 |
|
|
2022
Q2 | $21K | Buy |
2,509
+413
| +20% | +$3.46K | ﹤0.01% | 4280 |
|
|
2022
Q1 | $29K | Sell |
2,096
-5,355
| -72% | -$74.1K | ﹤0.01% | 4248 |
|
|
2021
Q4 | $147K | Buy |
7,451
+1,971
| +36% | +$38.9K | ﹤0.01% | 3774 |
|
|
2021
Q3 | $176K | Buy |
5,480
+2,640
| +93% | +$84.8K | ﹤0.01% | 3447 |
|
|
2021
Q2 | $96K | Buy |
2,840
+993
| +54% | +$33.6K | ﹤0.01% | 3864 |
|
|
2021
Q1 | $69K | Sell |
1,847
-1,447
| -44% | -$54.1K | ﹤0.01% | 3877 |
|
|
2020
Q4 | $110K | Buy |
3,294
+2,176
| +195% | +$72.7K | ﹤0.01% | 3625 |
|
|
2020
Q3 | $41K | Sell |
1,118
-2,144
| -66% | -$78.6K | ﹤0.01% | 3589 |
|
|
2020
Q2 | $107K | Buy |
3,262
+21
| +0.6% | +$689 | ﹤0.01% | 3413 |
|
|
2020
Q1 | $83K | Buy |
3,241
+1,083
| +50% | +$27.7K | ﹤0.01% | 3419 |
|
|
2019
Q4 | $67K | Buy |
+2,158
| New | +$67K | ﹤0.01% | 3788 |
|